Business Wire

Mary Kay Inc. Advocates for Advancing Women’s Economic Empowerment and Gender Equality Through Series of Milestone Commitments & Partnerships Around the World

20.7.2021 16:03:00 EEST | Business Wire | Press release

Share

Mary Kay Inc., a global advocate for women’s empowerment and entrepreneurship, has furthered its commitment to advancing gender parity by releasing a position paper welcoming the European Commission’s Gender Equality Strategy for 2020 – 2025 and by joining the Generation Equality Forum Global Action Coalitions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005347/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

This month, Mary Kay also joined the “Drivers of change” Program at the Generation Equality Forum in Paris, France (June 30 - July 2). (Graphic: Mary Kay Inc.)

The position paper, which can be accessed here, echoes the strategy of the European Union on gender equality. According to the European Union: “The Strategy presents policy objectives and actions to make significant progress by 2025 towards a gender-equal Europe. The goal is a Union where women and men, girls and boys, in all their diversity, are free to pursue their chosen path in life, have equal opportunities to thrive, and can equally participate in and lead our European society.”

“Discriminatory laws, gender bias and stereotyping, violence against women and girls - these are all global issues and must be tackled in partnership with the public and private sectors and civil society organizations across the world,” said Julia Simon, Chief Legal & Diversity Officer at Mary Kay. “Achieving gender equality is critical to the survival of the planet and the rebuilding of more sustainable and thriving economies and societies.”

This month, Mary Kay also joined the “Drivers of change” Program at the Generation Equality Forum in Paris, France (June 30 - July 2). 26 years after the Beijing Declaration, the Generation Equality Forum, convened by UN Women and co-hosted by the governments of Mexico and France, was the “most critical moment in a generation to invest in gender equality and accelerate momentum for women’s safety, leadership and economic opportunity1.”

Julia Simon participated to a panel titled “Building a Transformative Strategy for Gender-Responsive Procurement,” aiming at creating awareness of the disproportionately complex and interconnected barriers on women’s entrepreneurship and promoting gender-responsive procurement. Globally, 1 in 3 businesses are owned by women2, yet women win only 1% of the procurement spend of governments and large corporations3. Speakers shared insights and concrete advice substantiated by their own journey on how to implement a GRP strategy.

At the Paris Forum, Mary Kay also joined four of the Generation Equality Action Coalitions through policy, programmatic, and advocacy commitments: Economic Justice and Rights; Feminist Action for Climate Justice; Gender-based Violence and Innovation and Technology. 50,000 people virtually engaged in the Forum which gathered 1,000 commitment-makers, recorded $40 billion of investments for gender equality in support of a 5-year plan to act for equal across 6 areas of action.

These engagements are the latest of a series of Mary Kay’s advocacy efforts in support of women’s economic empowerment and gender equality at high level meetings around the world alongside its UN partners and local strategic partners.

  • On March 16, 2021, Deborah Gibbins, Mary Kay’s COO, joined the UN Global Compact Target Gender Equality meeting to discuss how Mary Kay empowers women entrepreneurs in nearly 40 countries. Gibbins highlighted the data freshly released by the World Bank4 revealing that, on average across the world, women have three quarters the legal rights of men. She challenged companies to take a stand against legal discriminations and advocate for reforms to close the gaps so that women can achieve their full potential. The event brought together over 5,000 people from the business sector, the United Nations, member states, and civil society organizations from over 100 countries, with 75% of the participants representing the private sector.
  • On March 24, 2021, on the sidelines of the Commission on the Status of Women (CSW65), Gibbins participated in a panel hosted by the Women’s Empowerment Accelerator (WEA) titled “Women Leading Economic Recovery Through Entrepreneurship” where she highlighted the need for public-private sector partnerships to help shape an enabling ecosystem for women entrepreneurs. Incepted by Mary Kay in collaboration with 5 UN agencies, The Women’s Entrepreneurship Accelerator was featured as an example of the unique impact of multi-partnership to accelerate change.
  • On March 26-April 4, Edita Szabóová, General Manager of Mary Kay Czech Republic and Slovakia, shared remarks at the Equal Pay Day Conference where she stressed the importance of “women supporting women,” and highlighted the work of Mary Kay in nurturing women entrepreneurs through training, leadership, and mentorship. “When women come together, we can achieve extraordinary things for the benefit of women and humanity at large. Because we know that if we lift one, we lift all. At its core, Mary Kay develops and trains entrepreneurs, who, in turn, get to build their own businesses and write their own stories and legacy for their daughters,” said Szabóová.
  • On June 15-16, 2021, at the UN Global Compact Leaders Summit, Gibbins spoke at the “Women In Sustainability: Innovating In A Man’s World” main stage session advocating for women entrepreneurs as the role models needed for the economy and society. She also emphasized the critical mission of the Women’s Entrepreneurship Accelerator incepted by Mary Kay together with 5 UN agency partners: UN Women, the UN Global Compact, International Trade Centre, the International Labour Organization and the UN Development Programme. The Accelerator has committed to educating and empowering 5 million women entrepreneurs over the next 10 years. “Women entrepreneurship will play a key role in the successful pandemic recovery. This is why the mission of the Women’s Entrepreneurship Accelerator is so timely. And, this is why women entrepreneurs need a framework of this magnitude,” said Gibbins. The annual Summit convened virtually more than 25,000 leaders from business, government, the UN, and civil society, to take stock of the state of progress and to drive collective action towards alleviating climate crisis, global pandemic, economic disparities, and social inequalities.
  • On July 6, in Ekaterinburg, Mary Kay joined the International Industrial Trade Fair INNOPROM-2021 the main industrial, trade and export platform in Russia. Guest speaker at a panel hosted by UN Women titled “UN Women Programs for the Promotion and Development of Gender-Based Entrepreneurship,” Mary Kay highlighted the critical importance of gender-responsive procurement strategies and emphasized that the pandemic also brings a unique opportunity to advance action and to support women’s businesses around the world.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company almost 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at www.marykay.com

1 https://forum.generationequality.org/home
2 World Bank (2020). Enterprise Surveys, World Bank Gender Data Portal cited by World Bank Blogs (2020) Women entrepreneurs needed – stat!
3 Vazquez and Sherman (2014). Cited by UN Women (2017) The Power of Procurement: How to source from women-owned businesses.
4 Women, Business and the Law, 2021. A report conducted in 190 countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye